Targeted delivery of cyclopropylbenzindole-containing cytotoxic

Details Targeted delivery of cyclopropylbenzindole-containing cytotoxic Targeted delivery of cyclopropylbenzindole-containing cytotoxic

1995-06-06

1998-12-08

Achutamurthy, Ponnathapura

Drug, bio-affecting and body treating compositions

Antigen, epitope, or other immunospecific immunoeffector

Conjugate or complex

4241941, 4241931, 4241981, 4241781, 530399, 5303917, 5303919, A61K 3818

Patent

active

058465456

ABSTRACT:
Gytotoxic agents containing a cell binding agent chemically linked to one or more analogue or derivative of CC-1065 are described. The therapeutic use of the cytotoxic agents is also described. These cytotoxic agents have therapeutic use because they deliver the cytotoxic drugs to a specific cell population in a targeted fashion.

REFERENCES:
patent: 4169888 (1979-10-01), Hanka et al.
patent: 4301248 (1981-11-01), Nettleton et al.
patent: 4912227 (1990-03-01), Kelley et al.
patent: 5045451 (1991-09-01), Uhr et al.
patent: 5087616 (1992-02-01), Myers et al.
patent: 5106951 (1992-04-01), Morgan et al.
patent: 5135736 (1992-08-01), Anderson et al.
Boyer et al., Antibody, Innumoconjugates and Radiopharmaceuticals, vol. 1, No. 2, pp. 105-162, 1988.
Waldmann, Science, vol. 252, pp. 1657-1662 (1991).
Roitt et al., Immunology, 3rd Edition, Mosby, St. Louis, pp. 17-19 (1993).
Osband et al., Immunology Today, vol. 11, No. 6, 1990, pp. 193-195.
U.S.A.N. 07/513,501, Paul A. Aristoff et al, Novel CC-1065 Analogs, Oct. 31, 1991, pp. 1-119, (publically available from WIPO).
Hermentin et al., Behring Inst. Mitt., No. 82, pp. 197-215 (1988).
Pierce Catalog, pp. E10-E45 (1992).
Carroll and Greene, Antibodies in Radiodiagnosis and Therapy, Zalutsky (Ed.) CRC Press, Boca Raton, Florida, pp. 13-43 (1989).
Coulter Catalog, pp. 27,34-35 and 40-41 (1992).
Pierce Catalog, pp. E10-E15, E20 and E44 (1991).
Kirkwood et al., Journal of Clinical Onocology, vol. 5, No. 8, pp. 1247-1255 (1987).
Murray et al., J. Nucl. Med., vol. 28, pp. 25-33 (1987).
Coulter Catalog, pp. 5-6, (1992).
Borrebaeck, Journal of Immunological Methods, vol. 123, pp. 157-165 (1989).
Boger et al., Bioorganic & Medicinal Chemistry Letters, vol. 1, No. 2, pp. 115-120 (1991).
Reynolds et al., "The Chemistry Mechanism of Action and Biological Properties of CC-1065 A Potent Antitumor Antibiotic", Mar. 1986, pp. 319-334 (The Jour. of Antibiotics, vol. XXXIX, No. 3).
Martin et al., "CC-1065 Transformations", Jun. 1985, pp. 745-752, The Journal of Antibiotics, vol. XXXVIII, No. 6.
Warpehoski et al., "Stereoelectronic Factors Influencing the Biological Acitivity and DNA Interaction of Synthetic Antitumor Agents Modeled on CC-1065", 1988, pp. 590-603, J. Med. Chem., 31.
Ravi et al., "Immunoconjugates Containing Novel Maytansinoids: Promising Anticancer Drugs", Jan. 1, 1992, pp. 127-131, Cancer Research, 52.
Boger et al., A Potent, Simple Derivative of an Analog of the CC1065 Alkylation Subunit, 1991, pp. 55-58, Bioorganic & Medicinal Chemistry Letters, vol. 1, No. 1.
McGovren et al., "Preliminary Toxicity Studies with the DNA-Binding Antibiotic, CC-1065", Jan. 1984, pp. 63-70, The Journal of Antibiotics, vol. XXXVII, No. 1.
Hanaka et al., "CC-1065 (NSC-298223), A new Antitumor Antiobiotic Production, In Vitro Biological Activity, Microbiological Assays and Taxonomy of the Producing Microoranism", Dec. 1978, pp. 1211-1217, The Journal of Antibiotics, vol. XXXI, No. 12.
Gomi et al., "Anticellular and Antitumor Activity of Duocarmycons Novel Antitumor Antibiotics", JPN J. Cancer Res., vol. 83, No. 1, pp. 113-120, 1992.
Riganti et al., "The Unique Interaction with Immunity of FCE 24517, an Antitumor Drug with a Novel Mode of Action", Int. J. Immunopharm., (United Kingdom), vol. 14, No. 2, pp. 239-251, 1992.
Lee et al., "Determination of the Structural Features of (+)-CC-1065 that are Responsible for Bending and Winding of DNA", Chem. Res. Toxicol., (USA), vol. 4, No. 2, pp. 203-213, 1991.
Swenson et al., "Evaluation of DNA binding characteristics of some CC-1065 Analogs", Chem. Biol. Interact., vol. 67, No. 3-4, pp. 199-213, 1988.
Li et al., "Adozelesin, a Selected Lead Among Cyclopropylpyrroloindole Analogs of the DNA-Binding Antibiotic, CC-1065", Invest. New Drugs, vol. 9, No. 2, pp. 137-148, 1991.
Ennis et al., "The EGF Receptor System as a Target for Antitumor Therapy", Cancer Invest., vol. 9, No. 5, pp. 553-562, 1991.
Gutowski et al., "Epidermal Growth Factor Receptor-reactive Monoclonal Antibodies: Xenograft Antitumor Activity Alone and as Drug Immunoconjugates", Cancer Res., vol. 51, No. 20, pp. 5471-5475, 1991.
Pardridge et al., "Selective Transport of an Anti-transferrin Receptor Antibody Through the Blood-brain barrier in vivo", J. Pharmacol. Exp. Ther., vol. 259, No. 1, pp. 66-70, 1991.
Boger, D.L. et al.: J. Org. Chem., vol. 55, 1990, pp. 5823-5833.
Boger, D.L. et al.: Biorg. Med. Chem. Lett., vol. 1, 1991, pp. 115-120.
Organic Chemistry, 3rd ed., p. 727.
Hack's Chemical Dictionary, 4th ed., 9. 35.

Affiliated with

Also associated with

Rating

Targeted delivery of cyclopropylbenzindole-containing cytotoxic does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Targeted delivery of cyclopropylbenzindole-containing cytotoxic , we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Targeted delivery of cyclopropylbenzindole-containing cytotoxic will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-174630